ADMA Biologics Inc $ADMA Shares Acquired by Jump Financial LLC

Key Points

• Jump Financial LLC significantly increased its stake in ADMA Biologics, raising it by 1,420.0% during the first quarter, acquiring an additional 333,752 shares and owning approximately 0.15% of the company at the end of that quarter.
• Multiple institutional investors, including SVB Wealth LLC and Price T Rowe Associates Inc. MD, expanded their positions in ADMA Biologics, with institutional ownership now at 75.68%.
• Brokerage firms have mixed ratings on ADMA Biologics, with Raymond James Financial upgrading their target price to $32.00, while Wall Street Zen downgraded their rating to "sell".

Jump Financial LLC grew its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 1,420.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 357,256 shares of the biotechnology company's stock after purchasing an additional 333,752 shares during the period. Jump Financial LLC owned about 0.15% of ADMA Biologics worth $7,088,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Skandinaviska Enskilda Banken AB publ purchased a new stake in ADMA Biologics in the first quarter worth $35,000. SVB Wealth LLC purchased a new stake in ADMA Biologics in the first quarter worth $35,000. Smartleaf Asset Management LLC increased its stake in ADMA Biologics by 161.4% in the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 1,493 shares during the period. Tsfg LLC purchased a new stake in ADMA Biologics in the first quarter worth $51,000. Finally, Brooklyn Investment Group increased its stake in ADMA Biologics by 28,655.6% in the first quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock worth $51,000 after purchasing an additional 2,579 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Up 0.8%

ADMA stock traded up $0.13 during trading on Thursday, reaching $17.38. 2,100,631 shares of the company traded hands, compared to its average volume of 3,110,884. ADMA Biologics Inc has a 12 month low of $13.50 and a 12 month high of $25.67. The business has a 50 day simple moving average of $17.77 and a 200 day simple moving average of $18.88. The company has a market capitalization of $4.15 billion, a price-to-earnings ratio of 20.21 and a beta of 0.38. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The company had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. During the same quarter last year, the company earned $0.13 earnings per share. The firm's revenue for the quarter was up 13.8% compared to the same quarter last year. On average, equities research analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial increased their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $27.67.

Insider Activity at ADMA Biologics

In related news, Director Jerrold B. Grossman sold 10,000 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the sale, the director owned 478,194 shares of the company's stock, valued at $10,190,314.14. This trade represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director directly owned 87,330 shares in the company, valued at approximately $1,767,559.20. The trade was a 69.04% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 455,621 shares of company stock valued at $9,461,633 over the last quarter. 3.50% of the stock is owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.